MARCHF3 and metabolic dysfunction-associated steatotic liver disease: Targeting the inhibition of MARCH3 can alleviate liver ferroptosis and lipid accumulation induced by intermittent hypoxia, thus slowing the progression of nonalcoholic fatty liver disease (NAFLD).